Treatments

*March 2022* Note: Those who progress on osimertinib and/or chemo with no actionable mutations are candidates for this treatment since HER3 overexpression is found in many EGFR+ lung cancer tumors. Disease progression and acquired resistance to approved EGFR tyrosine kinase inhibitors (TKIs) have resulted in a treatment void in the third- and…

*March 2022* Note: In this article,  Julien Mazieres, MD, PhD, talks R2D2, while Bob Li, MD, PhD, MPH, highlights DESTINY-Lung01 Also note: In the Destiny trial, Drug-related interstitial lung disease (ILD) and pneumonitis remain an important, identifiable risk. The R2D2 trial achieved a first by showing that HER2 mutations can be "treatable targets" in…

*March 2022* PURPOSE Patients with EGFR-mutant non-small cell lung cancer (NSCLC) experience variable duration of benefit on EGFR tyrosine kinase inhibitors (TKI). The effect of concurrent genomic alterations on outcome has been incompletely described. MATERIAL AND METHODS In this retrospective study, targeted next-generation sequencing data was collected from patients with EGFR-mutant lung…

*March 2022* Highlights: The EGFR-TKI efficacy of uncommon EGFR mutations generally considered TKI-sensitive was validated. Complex EGFR mutations containing exon19del or L858R mutations were EGFR TKI sensitive, independent of the combination partner. Very rare single and complex mutations, comprising 40% of atypical mutations, show a high heterogeneity of TKI sensitivity. TP53 co-mutations may confer…

*March 2022* The first patient with advanced non–small cell lung (NSCLC) in the phase 1/2 Acclaim-1 clinical trial had been dosed with quaratusugene ozeplasmid (Reqorsa) in combination with osimertinib (Tagrisso) after disease progression on osimertinib alone, according to a press release issued by Genprex, Inc.1 Quaratusugene ozeplasmid is an immunogene…

*March 2022* To build on the advances that have been made in lung cancer over the past several years, researchers have their sights set on improving the efficacy of immunotherapy with novel approaches, the ability to overcome acquired resistance to targeted therapies, and the accessibility to molecular testing and approved…

*March 2022* Adding bevacizumab to the use of erlotinib (Tarceva) in patients with EGFR-mutated non–small cell lung cancer (NSCLC) did not prolong their survival. However, both treatment arms with and without bevacizumab (Avastin) had relatively long survival durations that encouraged researchers, according to study results published in the Lancet. Read more.

*April 2022* In this video, EGFR Resisters co-founder Ivy Elkins does an interview with Rasheda Persinger, MedOnc Nurse Practioner for JADPRO’s Biomarkers in NSCLC Resource Center. It covers how to best discuss biomarker testing, treatments and symptoms with patients diagnosed with lung cancer. Your healthcare team should use clear, understandable…

*February 2022* A growing recognition of the distinct clinical, pathological, and biological features of lung cancers that arise in nonsmokers is fostering greater interest in examining the molecular underpinnings of lung cancer in this patient subset. During the past 2 decades, the treatment of patients with lung cancer has undergone…

*February 2022* The FDA’s Oncologic Drugs Advisory Committee voted against using single-country foreign data to support a biologics license application (BLA) for sintilimab injection plus pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous non–small cell lung cancer (NSCLC). ODAC concluded that supporting data from the phase…